Risk of treatment-related mortality in cancer patients treated with ipilimumab: A systematic review and meta-analysis

This publication has 29 references indexed in Scilit:

• Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study
  The Lancet Oncology, 2017
• Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial
  The Lancet Oncology, 2016
• Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
  Proceedings of the National Academy of Sciences, 2015
• Incidence and risk of treatment-related mortality in cancer patients treated with the mammalian target of rapamycin inhibitors
  Annals of Oncology, 2013
• Management of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
  Journal of Clinical Oncology, 2012
• Meta-Analysis of Randomized Controlled Trials for the Incidence and Risk of Treatment-Related Mortality in Patients With Cancer Treated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitors
  Journal of Clinical Oncology, 2012
• Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
  New England Journal of Medicine, 2011
• Treatment-Related Mortality With Bevacizumab in Cancer Patients
  JAMA, 2011
• Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
  New England Journal of Medicine, 2010
• Incidence of Adverse Drug Reactions in Hospitalized Patients
  JAMA, 1998